Oruka (ORKA) CCO Larry Todd Edwards Receives 120,000-Share Award

What Happened

• Larry Todd Edwards, Chief Commercial Officer of Oruka Therapeutics (ORKA), received two awards on August 24, 2026: a 100,000-share award (non-derivative) and a 20,000-share derivative award (option). Both were granted at $0.00 (no cash paid at grant), totaling 120,000 shares awarded on that date. These are grants/awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-08-24; SEC Form 4 filed 2026-08-25 (appears timely).
• Grant amounts and prices: 100,000 shares @ $0.00 (award); 20,000 derivative shares @ $0.00 (option/derivative).
• Shares owned after transaction: Not specified in the filing.
• Vesting footnotes:
  • F1 (100,000-share award): 1/4 vests on September 14, 2027; remaining shares vest in 12 equal quarterly installments thereafter.
  • F2 (20,000 derivative/option): 1/4 of underlying shares vest on August 24, 2027; then 1/48 of underlying shares vest monthly thereafter.
• Transaction code: A = Award/Grant. No purchase (P) or sale (S) reported; not an exercise or cashless sale.

Context

• These are compensation grants subject to multi-period vesting, so shares will not be immediately tradable and are intended as employee incentives rather than open-market purchases. The derivative award is an option-style grant with a standard multi-year vest schedule; it was granted, not exercised. No indication in the filing of tax withholding, 10b5-1 plan usage, or late filing.